Common adverse event reporting form
Final version of a common form for reporting adverse events associated with drugs, biologics and devices will be the topic of a June 3 FDA-sponsored conference involving representatives from the affected industries and health care professionals. A final version of the form is slated for Federal Register publication around the time of the meeting; a draft was issued in February. Health Research Group has asked FDA to delay implementation of the new form until after its effectiveness is compared to existing forms in a six-month field trial.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth